Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 3-[1-(4-bromo-phenyl)-2-methyl-propyl]-4-hydroxy-chromen-2-one is a synthetic small molecule belonging to the class of coumarins, specifically a chromenone derivative. It features a brominated phenyl group and a hydroxy group at the chromenone core. This compound is structurally related to other coumarin derivatives, which are known for their anticoagulant and anti-inflammatory properties. However, this specific compound is classified as experimental and has not been approved for any therapeutic use or entered clinical trials beyond preclinical investigation[1][2][8]. Its mechanism of action has not been established in the literature or major drug databases[9]. The compound may have potential anti-inflammatory activity based on its chemical class but lacks published pharmacological data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[1-(4-bromo-phenyl)-2-methyl-propyl]-4-hydroxy-chromen-2-one.